Kabra Drugs Ltd (524322)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Kabra Drugs' revenue was ₹46.2 Cr (+546.4% year on year, +30.5% on the previous quarter), and net profit ₹2.1 Cr (against a loss a year earlier); the operating margin was 6.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹46.2 | +546.4% | +30.5% |
| Operating profit | ₹2.8 | from loss | +108.2% |
| Net profit | ₹2.1 | from loss | +100.3% |
| EPS (₹) | 0.90 | from loss | +100.0% |
| Operating margin | 6.0% | — | — |
📢 Recent Corporate Announcements
Kabra Drugs Ltd (Aanjaay Industries Limited) has completed the relocation of its registered office from Indore, Madhya Pradesh to West Mambalam, Chennai, Tamil Nadu. The inter-state shift was approved by the Regional Director on August 13, 2026, and registered with ROC Chennai on August 28, 2026. This administrative update follows the statutory approvals under Section 13(5) of the Companies Act, 2013, with paid-up capital standing at Rs 23.71 Cr.
- Registered office shifted from Indore, MP (ROC Gwalior) to Chennai, Tamil Nadu (ROC Chennai)
- Shift effective from August 28, 2026 following RD order dated August 13, 2026
- Paid-up capital reported at Rs 23,70,78,500 against an authorised capital of Rs 40,00,00,000
Kabra Drugs Ltd (now Aanjaay Industries Limited) has scheduled a Board of Directors meeting on September 2, 2026. The board will approve the Directors' Report for the financial year ended March 31, 2026, and finalize the date and cut-off details for the upcoming Annual General Meeting (AGM). Additional agenda items include the re-appointment of director Mr. Kuniamuthur Nanjappan Anand, the proposed appointment of Ms. Moonam Kapoor as director, and appointment of internal and secretarial auditors.
- Board meeting scheduled for September 2, 2026 at the Corporate Office in Chennai
- Meeting to approve the Directors' Report and Corporate Governance Report for FY ended March 31, 2026
- To propose the appointment of Ms. Moonam Kapoor (DIN: 09278005) as Director
- To recommend Secretarial Auditor appointment for FY 2026-2027 to 2030-2031
Kabra Drugs Limited (formerly known as Aanjaay Industries Limited) announced the reconstitution of its Board of Directors and key committees with effect from August 12, 2026. The 5-member board consists of 2 Executive Directors and 3 Non-Executive Independent Directors, led by Managing Director Nanjappan Aravind. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees have also been restructured with independent director majorities.
- Reconstitution of Board and committees effective August 12, 2026
- Board comprises 5 total directors: 2 Executive and 3 Independent Non-Executive Directors
- Audit Committee reconstituted with 3 members, chaired by Independent Director Nikita Sinha
- Nomination & Remuneration Committee formed with 3 members, chaired by Independent Director Ritu Tiwari
Ms. Anand Anitha has resigned from her position as Director of Kabra Drugs Ltd (now Aanjaay Industries Limited) effective August 12, 2026. The resignation is attributed to personal reasons, with the director confirming there are no other material reasons for her departure. This management change occurs as the company, with a market capitalization of ₹56 Cr, manages a significant scale-up from zero revenue in FY25 to ₹92.74 Cr in FY26. The board has taken note of the resignation following recommendations from the Nomination and Remuneration Committee.
- Resignation of Ms. Anand Anitha effective from August 12, 2026
- Director confirmed no other material reasons for resignation beyond personal grounds
- Company reported FY26 revenue of ₹92.74 Cr compared to zero in FY25
- Current Market Capitalization stands at ₹56 Cr
Aanjaay Industries Limited (formerly Kabra Drugs Limited) has submitted a formal undertaking to the BSE regarding Regulation 32 of SEBI (LODR). The company confirmed that it did not raise any funds through public, rights, or preferential issues for the quarter ended June 30, 2026. Consequently, there are no deviations or variations in the utilization of proceeds to report. This is a standard procedural filing required by listed entities to ensure transparency in fund usage.
- Reporting period ended June 30, 2026.
- Zero shares issued via public, rights, or preferential routes during the quarter.
- Filing submitted on August 12, 2026, as per SEBI (LODR) requirements.
Kabra Drugs (now Aanjaay Industries) reported a robust Q1 FY27 with revenue from operations at Rs 46.22 Cr, a massive 546% jump from Rs 7.15 Cr in Q1 FY26. The company posted a net profit of Rs 2.12 Cr, turning around from a loss of Rs 0.50 Cr in the year-ago period. Sequentially, revenue grew 30.5% from Rs 35.41 Cr in the March 2026 quarter. This single quarter's revenue represents nearly 50% of the total TTM revenue, indicating a significant acceleration in business scale.
- Revenue from operations reached Rs 46.22 Cr, up 546% from Rs 7.15 Cr in the same quarter last year
- Net profit turned positive at Rs 2.12 Cr compared to a loss of Rs 0.50 Cr in Q1 FY26
- Basic EPS for the quarter improved to Rs 0.90 from Rs 0.45 in the preceding March 2026 quarter
- Purchases of stock-in-trade stood at Rs 49.03 Cr, indicating a high-volume trading-led business model
Kabra Drugs (now Aanjaay Industries) reported a significant turnaround in Q1 FY27, with revenue surging to Rs 46.22 Cr compared to Rs 7.15 Cr in the same quarter last year. The company posted a net profit of Rs 2.12 Cr, reversing a loss of Rs 0.50 Cr in Q1 FY26. This single quarter's revenue represents approximately 50% of the total TTM revenue of Rs 93 Cr. The results highlight a heavy reliance on stock-in-trade purchases (Rs 49.03 Cr), suggesting a high-volume, low-margin trading business model.
- Revenue from operations increased 546% YoY to Rs 46.22 Cr from Rs 7.15 Cr.
- Net profit turned positive at Rs 2.12 Cr compared to a loss of Rs 0.50 Cr in the year-ago period.
- Quarterly EPS improved significantly to Rs 0.90 from a negative Rs 0.21.
- Purchases of stock-in-trade reached Rs 49.03 Cr, indicating a major scale-up in trading activity.
- Total expenses for the quarter stood at Rs 43.45 Cr, driven primarily by procurement costs.
Kabra Drugs Ltd (now Aanjaay Industries) has scheduled a board meeting for August 12, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The board will also consider the resignation of Director Ms. Anand Anitha. This meeting follows a high-growth FY26 where the company scaled revenue to Rs 92.74 Cr from zero in FY25. Investors should focus on whether the company can maintain its TTM operating margin of 5.7% and the revenue momentum seen in the March 2026 quarter (Rs 35.41 Cr).
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
- Resignation of Director Ms. Anand Anitha (DIN: 02040505) to be formally considered.
- Trading window for insiders is closed until 48 hours after the results announcement.
- Company reported a significant turnaround in FY26 with Rs 4.96 Cr PAT vs a loss of Rs 1.09 Cr in FY25.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
